Navigation Links
EntreMed Presents Initial Clinical Results for ENMD-2076
Date:2/9/2009

a A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commissio
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...re/ -- Reportlinker.com announces that a new marke..., Mammography Equipment - A Global Market Per...4330/Mammography-Equipment---A-Global-Market-Persp...er in industrialized as well as developing nations...ammography market. Globally, escalating awareness ...
(Date:11/25/2009)...RNewswire/ -- Cempra Pharmaceuticals Inc. today an...chief executive officer, will present at the Piper...0 a.m. EST, December 1, 2009, at The New York Pala...vide an overview of the company,s two leading anti...-resistant pathogens including MRSA. ,, About ...
(Date:11/25/2009)...Newswire/ -- ChemoCentryx, Inc., announced today...s PROTECT-1 (the Prospective Randomized Oral Thera...t-EN(TM) (CCX282-B) in patients with moderate-to-s...cy with a favorable safety and tolerability profil...ficacy in the reduction of disease severity as def...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 1Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 2Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media 6219 3SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 10712 1SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 10712 2Study Links Yo Yo Dieting to Addiction 61264 1Study Links Yo Yo Dieting to Addiction 61264 2Study Links Yo Yo Dieting to Addiction 61264 3
...E: SHP,Nasdaq: SHPGY), the global specialty biopha...ientific meeting findings from analyses of pivotal...onist. This compound is an,investigational once-da...reatment of the symptoms of Attention Deficit Hype...hat INTUNIV showed significant efficacy in,reducin...
... Expected at ASCO in June -, SOUTH SAN FRANCISCO,...daq: PARD ), a biopharmaceutical company focused,... patient enrollment in,its Phase 2 clinical trial ... the first-line treatment of metastatic colorectal...cted in the second half of 2008. Picoplatin,the Co...
Other Medicine Technology:Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 2Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 3Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 4
(Date:11/27/2009)...ov. 27 Preventing disea...ortunately every year, new vaccines are being adde...ines boost immunity for the same period of time? A...eded to keep immunity strong? ,, In this mont...an Academy of Pediatrics, Michael Pichichero MD, D...
(Date:11/27/2009)...dented medical, economic burdens, study predicts ,...he number of people with diabetes in the United St... a new study predicts. , That would bring the t... disease, up from 23.7 million today. , , At the...tes will triple, the study also warns, rising from...
(Date:11/27/2009)...e new interactive anatomy education apps from Moda...health sciences learning opportunities for iPhone ...NC (Vocus) November 27, 2009 -- Modality, Inc. a...sion of Wolters Kluwer Health, today announced the...on the App Store. Clemente’s Anatomy, Rohen&...
(Date:11/26/2009)...heavy can lead to strains or worse , , T...nothing wrong with stuffing your turkey full to bu...g with your suitcase as you pack for holiday trips...8 in U.S. hospital emergency rooms, doctors, offic...ge-related injuries, such as muscle strains, pulls...
(Date:11/26/2009)...on Communications announces a highly effective and...rs struggling to make an economic recovery. , ...Flu fears is the type of challenge that could send...ding to Dr. David Benton, business growth expert a...stem – The Rfactor Intensive . “Fea...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Pharmacist Injects Cure for Ailing Businesses 2
...ative Legume Research (CILR) have screened legumes...il bacteria// in their roots, for biological activ...ch could potentially prevent the formation of a bl...application for compounds to treat cancer. ...
...th breast cancer in England has started a protest ...rug treatment// at a hospital. Local health boards...like the Shropshire Primary Care Trust. The patien...at breast cancer patients from Wales are getting t...
...ually snoring parents are also at an increased ris...esearchers have also found that children with atop... for chronic snoring. Sleep-disordered breat...ow becomes obstructed, the throat and tongue vibra...
... Inc., a U.S. biopharmaceutical company, Cesario V... at the Medical College of Georgia in Augusta and ...s into the brains of rats that had suffered stroke...American Academy of Neurology annual meeting, in S...
...hropshire and parts of Wales. Breast cancer patien... drug Herceptin but Welsh women get it for free. /...re Trust in Shropshire refused to pay for Hercepti... for the drug for women living in Wales even if th...
...tage, localized breast cancer new patterns and ris...d that may influence how patients are treated. // ...rom 1988 to 2002 was reviewed by Cancer Research C...t DCIS and LCIS develop. The authors noted t...
Other Medicine News:Health News:Compounds In Legume May Be Helpful In Treating Cancer 2Health News:Cancer Patients Protest For Free Drug Treatment 2Health News:Snoring Runs in the Family 2Health News:Neurological Damage Can Be Reduced By Stem Cell Transplants 2Health News:Free Herceptin Treatment for Those Who Live Over the Welsh Border 2
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: